{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-014559","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2024-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.036586+00:00","generated_at":"2026-06-03T22:54:51.642196+00:00","sec_items":["3.02","8.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"RenovoRx closes $11.1M private placement; total 2024 raise $17.2M, funds Phase III trial into 2026","bullets":["Gross proceeds of $11.1M from private placement of common stock, pre-funded, Series A, B, and placement agent warrants.","Net proceeds estimated at ~$9.6M; total gross proceeds raised in 2024 now $17.2M from two placements.","Issued 6,960,864 common shares, pre-funded warrant for 951,500 shares, Series A/B warrants for 7.9M and 3.96M shares.","Proceeds for working capital, Phase III TIGeR-PaC trial in LAPC, and pipeline expansion into additional cancer indications.","Company expects cash runway into 2026; second interim analysis for TIGeR-PaC estimated in late 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-014559","json":"https://secwatch.observer/filing/0001493152-24-014559.json","markdown":"https://secwatch.observer/filing/0001493152-24-014559.md","text":"https://secwatch.observer/filing/0001493152-24-014559.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000149315224014559/0001493152-24-014559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000149315224014559/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:54:51.642196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}